April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Effects of the treatment with intravitreal injection of Ranibizumab for Diabetic Macular Edema.Our Experience: 30 month Follow up
Author Affiliations & Notes
  • lucia comastri
    RETINA, Hospital de Clincas, Buenos Aires, Argentina
  • Matias Iglicki
    RETINA, Hospital de Clincas, Buenos Aires, Argentina
  • Juan Pablo Francos
    RETINA, Hospital de Clincas, Buenos Aires, Argentina
  • Juan Manuel Cortalezzi
    RETINA, Hospital de Clincas, Buenos Aires, Argentina
  • Diego Bar
    RETINA, Hospital de Clincas, Buenos Aires, Argentina
  • Carmen N Demetrio
    RETINA, Hospital de Clincas, Buenos Aires, Argentina
  • Mario J Saravia
    RETINA, Hospital de Clincas, Buenos Aires, Argentina
  • Jorge Bar
    RETINA, Hospital de Clincas, Buenos Aires, Argentina
  • Pablo Chiaradia
    RETINA, Hospital de Clincas, Buenos Aires, Argentina
  • Marcelo Zas
    RETINA, Hospital de Clincas, Buenos Aires, Argentina
  • Footnotes
    Commercial Relationships lucia comastri, None; Matias Iglicki, None; Juan Pablo Francos, None; Juan Manuel Cortalezzi, None; Diego Bar, None; Carmen Demetrio, None; Mario Saravia, None; Jorge Bar, None; Pablo Chiaradia, None; Marcelo Zas, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1769. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      lucia comastri, Matias Iglicki, Juan Pablo Francos, Juan Manuel Cortalezzi, Diego Bar, Carmen N Demetrio, Mario J Saravia, Jorge Bar, Pablo Chiaradia, Marcelo Zas, ; Effects of the treatment with intravitreal injection of Ranibizumab for Diabetic Macular Edema.Our Experience: 30 month Follow up. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1769.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To present the effects of the treatment with intravitreal injection of Ranibizumab (lucentis) for Diabetic Macular Edema:

 
Methods
 

The Study included 8 patients with diabetic macular edema with or whiout previous Argon LASER and with or whitout previous neovascularization.The diagnosis and monitoring of the treatment were done by means of best correction visual acuity ( BCVA) with ETDRS chart , symptoms, fluorescein angigraphy and optical coherence tomography ( OCT) . The patients were monitored 7 and 30 days after the injection

 
Results
 

30 days after the injection of ranibizumab (Lucentis) 0,05mg (0,5ml), BCVA had improved in 7 of 8 patients; they had improved 3 lines at reading letters on the ETDRS chart. The OCT showed an improvement in the retinal architecture in all patients: the retinal thickness reduced an average of 60 micrometres and has remained at that level up to the present (30 months follow-up).

 
Conclusions
 

One of the causes of diabetic macular edema is the increase of the permeability of the hematoretinal barrier, the VEGF is an important factor in this kind of increase. Thus, anti VEGF could be a possible treatment for this pathology. Further follow-up of the BCVA, OCT and symptoms is needed to decide whether retreatment is required.

     
Keywords: 498 diabetes • 585 macula/fovea • 505 edema  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×